News|Articles|April 8, 2026

Q1 2026 Recap: Psychiatry News and Updates

Fact checked by: Tim Smith

FDA approvals, at-home neuromodulation, phase 3 psychedelic data, and rising AI therapy use impacted the psychiatry field in the first quarter of 2026.

The first quarter of 2026 brought regulatory approvals, late-stage psychedelic data, and increased use of at-home neuromodulation and artificial intelligence–supported mental health tools that reflected rapid change across psychiatry. US Food & Drug Administration (FDA) decisions expanded treatment options for acute bipolar I disorder, schizophrenia, and major depressive disorder (MDD), alongside progress toward a potential new nonstimulant therapy for ADHD.